Accessibility Statement Skip Navigation
  • Why PRWeb
  • How It Works
  • Who Uses It
  • Pricing
  • Login
  • GDPR
  • Create a Free Account
Return to PRWeb homepage
  • News
  • Resources
  • Contact
When typing in this field, a list of search results will appear and be automatically updated as you type.

Searching for your content...

No results found. Please change your search terms and try again.
  • News in Focus
      • Browse News Releases

      • All News Releases
      • Multimedia Gallery

      • All Multimedia
      • All Photos
      • All Videos
  • Business & Money
      • Auto & Transportation

      • Aerospace, Defense
      • Air Freight
      • Airlines & Aviation
      • Automotive
      • Maritime & Shipbuilding
      • Railroads and Intermodal Transportation
      • Supply Chain/Logistics
      • Transportation, Trucking & Railroad
      • Travel
      • Trucking and Road Transportation
      • View All Auto & Transportation

      • Business Technology

      • Blockchain
      • Broadcast Tech
      • Computer & Electronics
      • Computer Hardware
      • Computer Software
      • Data Analytics
      • Electronic Commerce
      • Electronic Components
      • Electronic Design Automation
      • Financial Technology
      • High Tech Security
      • Internet Technology
      • Nanotechnology
      • Networks
      • Peripherals
      • Semiconductors
      • View All Business Technology

      • Entertain­ment & Media

      • Advertising
      • Art
      • Books
      • Entertainment
      • Film and Motion Picture
      • Magazines
      • Music
      • Publishing & Information Services
      • Radio & Podcast
      • Television
      • View All Entertain­ment & Media

      • Financial Services & Investing

      • Accounting News & Issues
      • Acquisitions, Mergers and Takeovers
      • Banking & Financial Services
      • Bankruptcy
      • Bond & Stock Ratings
      • Conference Call Announcements
      • Contracts
      • Cryptocurrency
      • Dividends
      • Earnings
      • Earnings Forecasts & Projections
      • Financing Agreements
      • Insurance
      • Investments Opinions
      • Joint Ventures
      • Mutual Funds
      • Private Placement
      • Real Estate
      • Restructuring & Recapitalization
      • Sales Reports
      • Shareholder Activism
      • Shareholder Meetings
      • Stock Offering
      • Stock Split
      • Venture Capital
      • View All Financial Services & Investing

      • General Business

      • Awards
      • Commercial Real Estate
      • Corporate Expansion
      • Earnings
      • Environmental, Social and Governance (ESG)
      • Human Resource & Workforce Management
      • Licensing
      • New Products & Services
      • Obituaries
      • Outsourcing Businesses
      • Overseas Real Estate (non-US)
      • Personnel Announcements
      • Real Estate Transactions
      • Residential Real Estate
      • Small Business Services
      • Socially Responsible Investing
      • Surveys, Polls and Research
      • Trade Show News
      • View All General Business

  • Science & Tech
      • Consumer Technology

      • Artificial Intelligence
      • Blockchain
      • Cloud Computing/Internet of Things
      • Computer Electronics
      • Computer Hardware
      • Computer Software
      • Consumer Electronics
      • Cryptocurrency
      • Data Analytics
      • Electronic Commerce
      • Electronic Gaming
      • Financial Technology
      • Mobile Entertainment
      • Multimedia & Internet
      • Peripherals
      • Social Media
      • STEM (Science, Tech, Engineering, Math)
      • Supply Chain/Logistics
      • Wireless Communications
      • View All Consumer Technology

      • Energy & Natural Resources

      • Alternative Energies
      • Chemical
      • Electrical Utilities
      • Gas
      • General Manufacturing
      • Mining
      • Mining & Metals
      • Oil & Energy
      • Oil and Gas Discoveries
      • Utilities
      • Water Utilities
      • View All Energy & Natural Resources

      • Environ­ment

      • Conservation & Recycling
      • Environmental Issues
      • Environmental Policy
      • Environmental Products & Services
      • Green Technology
      • Natural Disasters
      • View All Environ­ment

      • Heavy Industry & Manufacturing

      • Aerospace & Defense
      • Agriculture
      • Chemical
      • Construction & Building
      • General Manufacturing
      • HVAC (Heating, Ventilation and Air-Conditioning)
      • Machinery
      • Machine Tools, Metalworking and Metallurgy
      • Mining
      • Mining & Metals
      • Paper, Forest Products & Containers
      • Precious Metals
      • Textiles
      • Tobacco
      • View All Heavy Industry & Manufacturing

      • Telecomm­unications

      • Carriers and Services
      • Mobile Entertainment
      • Networks
      • Peripherals
      • Telecommunications Equipment
      • Telecommunications Industry
      • VoIP (Voice over Internet Protocol)
      • Wireless Communications
      • View All Telecomm­unications

  • Lifestyle & Health
      • Consumer Products & Retail

      • Animals & Pets
      • Beers, Wines and Spirits
      • Beverages
      • Bridal Services
      • Cannabis
      • Cosmetics and Personal Care
      • Fashion
      • Food & Beverages
      • Furniture and Furnishings
      • Home Improvement
      • Household, Consumer & Cosmetics
      • Household Products
      • Jewelry
      • Non-Alcoholic Beverages
      • Office Products
      • Organic Food
      • Product Recalls
      • Restaurants
      • Retail
      • Supermarkets
      • Toys
      • View All Consumer Products & Retail

      • Entertain­ment & Media

      • Advertising
      • Art
      • Books
      • Entertainment
      • Film and Motion Picture
      • Magazines
      • Music
      • Publishing & Information Services
      • Radio & Podcast
      • Television
      • View All Entertain­ment & Media

      • Health

      • Biometrics
      • Biotechnology
      • Clinical Trials & Medical Discoveries
      • Dentistry
      • FDA Approval
      • Fitness/Wellness
      • Health Care & Hospitals
      • Health Insurance
      • Infection Control
      • International Medical Approval
      • Medical Equipment
      • Medical Pharmaceuticals
      • Mental Health
      • Pharmaceuticals
      • Supplementary Medicine
      • View All Health

      • Sports

      • General Sports
      • Outdoors, Camping & Hiking
      • Sporting Events
      • Sports Equipment & Accessories
      • View All Sports

      • Travel

      • Amusement Parks and Tourist Attractions
      • Gambling & Casinos
      • Hotels and Resorts
      • Leisure & Tourism
      • Outdoors, Camping & Hiking
      • Passenger Aviation
      • Travel Industry
      • View All Travel

  • Policy & Public Interest
      • Policy & Public Interest

      • Advocacy Group Opinion
      • Animal Welfare
      • Congressional & Presidential Campaigns
      • Corporate Social Responsibility
      • Domestic Policy
      • Economic News, Trends, Analysis
      • Education
      • Environmental
      • European Government
      • FDA Approval
      • Federal and State Legislation
      • Federal Executive Branch & Agency
      • Foreign Policy & International Affairs
      • Homeland Security
      • Labor & Union
      • Legal Issues
      • Natural Disasters
      • Not For Profit
      • Patent Law
      • Public Safety
      • Trade Policy
      • U.S. State Policy
      • View All Policy & Public Interest

  • People & Culture
      • People & Culture

      • Aboriginal, First Nations & Native American
      • African American
      • Asian American
      • Children
      • Diversity, Equity & Inclusion
      • Hispanic
      • Lesbian, Gay & Bisexual
      • Men's Interest
      • People with Disabilities
      • Religion
      • Senior Citizens
      • Veterans
      • Women
      • View All People & Culture

  • Hamburger menu
  • Cision PRWeb provides efficient communication tools to continuously engage with target audiences across multiple online channels
  • Create a Free Account
    • ALL CONTACT INFO
    • Contact Us


      11AM ET Sunday – 8PM ET Friday

  • Send a Release
  • Sign up
  • Log in
  • Resources
  • RSS
  • GDPR
  • News in Focus
    • Browse All News
    • Multimedia Gallery
  • Business & Money
    • Auto & Transportation
    • Business Technology
    • Entertain­ment & Media
    • Financial Services & Investing
    • General Business
  • Science & Tech
    • Consumer Technology
    • Energy & Natural Resources
    • Environ­ment
    • Heavy Industry & Manufacturing
    • Telecomm­unications
  • Lifestyle & Health
    • Consumer Products & Retail
    • Entertain­ment & Media
    • Health
    • Sports
    • Travel
  • Policy & Public Interest
  • People & Culture
    • People & Culture
  • Send a Release
  • Sign up
  • Log in
  • Resources
  • RSS
  • GDPR
  • Send a Release
  • Sign up
  • Log in
  • Resources
  • RSS
  • GDPR
  • Send a Release
  • Sign up
  • Log in
  • Resources
  • RSS
  • GDPR

ClinOne to Support ERGOMED's New Rare Disease Innovation Centre with a Single Technology Platform to Raise Trial Awareness, Engage Patients, and Reduce Site Burden

Announced on Rare Disease Day 2022, partnership combines ClinOne's true single platform with ERGOMED Site Advantage™ to make it easier for patients to participate in, and for sites to run, global clinical trials


News provided by

ClinOne

Feb 28, 2022, 04:00 ET

Share this article

Share toX

Share this article

Share toX


DENVER and LONDON, Feb. 28, 2022 /PRNewswire-PRWeb/ -- ClinOne, the true single technology platform to connect, inform, and empower clinical trial patients and sites, has partnered with global clinical research organization ERGOMED plc (LSE: ERGO) to provide a range of clinical trial technologies for ERGOMED's newly launched Rare Disease Innovation Centre. The partnership will bring tangible benefits to sites, patients and caregivers globally, and help accelerate drug development for Rare Diseases.

The ClinOne platform will initially be used by ERGOMED to raise trial awareness and increase HCP activation among the Rare Disease community, with additional solutions available including caregiver support, medication adherence, and a decentralized clinical trials (DCT) portal to reduce site burden and improve the patient experience.

We’re honored to be part of ERGOMED’s Rare Disease Innovation Centre, and to join our colleagues to accelerate the development of new treatments, by reducing the site burden and making it easier for patients to participate. --Rob Bohacs, ClinOne Founder and Chief Solutions Officer

Post this

The announcement comes on Rare Disease Day, which recognizes the 300 million globally who have been diagnosed with a Rare Disease. 95% of Rare Diseases do not have a single FDA-approved drug therapy, which creates a unique opportunity for ClinOne and ERGOMED to have a significant and immediate impact on the lives of those affected by Rare Diseases globally.

30% of all investigational products globally are for Rare Diseases. ERGOMED's Site Advantage™ operating model is specifically designed to provide specialized support to research sites and patients participating in Rare Disease clinical research.

"Patients in Rare Disease clinical trials have unique requirements and deserve solutions that understand the way their condition affects not only their lives, but also those of their caregivers, family members, loved ones, and site team," said Rob Bohacs (LinkedIn), ClinOne Founder and Chief Solutions Officer. "In most Rare Disease trials, it's hard to find patients, it's hard to support caregivers and sites, and it's hard to collaborate meaningfully with healthcare providers outside of the trial. Thankfully, technology like ours has the potential to truly transform Rare Disease trials by reducing burden on sites and by making it easier for patients and caregivers to participate - without getting in the way of their daily lives. That's why we are so honored to be part of ERGOMED's new Rare Disease Innovation Centre, and to join our colleagues in their mission to accelerate the development of new treatments for global Rare Diseases."

Rare Disease drug development is one of the fastest growing areas in drug development with a 12-14% annual growth rate, accounting for about one third of the drugs in development.

"With our newly launched Rare Disease Innovation Centre, ERGOMED is proud and humbled to be a part of the solution for the historically underserved Rare Disease community," said Zizi Uzezi Imatorbhebhe, Senior Vice President, Global Strategy and Development, Head Rare Disease Innovation Centre, ERGOMED. "By combining our experience and expertise from running hundreds of Rare Disease clinical trials with modern technology from industry partnership like ClinOne, we will work together to solve challenges for sponsors who are committed to bringing exciting new therapeutics to market to improve the lives of Rare Disease patients and their families worldwide."

About ClinOne
ClinOne connects, informs, and empowers patients, caregivers, and sites in clinical trials with a true single platform for trial awareness, eConsent, medication adherence, Uber Health, eDiaries, and decentralized clinical trials (DCT). Used by more than 55 sponsors, CROs, and site networks in 60 countries, our solutions are proven to reduce risk and simplify complex processes for therapeutic areas and patient populations including Oncology, Rare Disease, Pediatrics, the Elderly, and CNS. Designed in collaboration with sites and with caregivers in mind, ClinOne features the industry's fastest deployment, cost-efficient scale for trials of all sizes, and seamless API integrations to provide the results you need – and the experience your patients deserve. Ready to keep patients, sites, and study teams active and engaged throughout your clinical trial? Let's get creative at http://www.clinone.com.

About ERGOMED
Founded in 1997, Ergomed plc is dedicated to the provision of specialized services to the pharmaceutical industry and the development of new drugs. With a global footprint covering 100+ countries, we have the reach to deliver solutions for even the toughest clinical development and trial management challenges.

ERGOMED has provided clinical development, trial management, and pharmacovigilance services for 300+ clients, from top 10 pharmaceutical and generics organizations to small and mid-sized drug development companies.

ERGOMED has been a pioneer in the Rare Disease Drug Development in addition to offering patient centric solutions and closely collaborating with patient advocacy groups to maximize sponsor success. For more information visit http://www.ergomedcro.com or email [email protected]

Media Contact

Brenda Nashawaty, ClinOne, +1 (617) 688-3253, [email protected]

Flo Denance Habek, ERGOMED plc, [email protected]

SOURCE ClinOne

Related Links

http://www.clinone.com

Modal title

Contact PRWeb

  • 11AM ET Sunday – 8PM ET Friday
  • Contact Us

About PRWeb

  • About PRWeb
  • Partners
  • Partnership Programs
  • Editorial Guidelines
  • Resources

Why PRWeb

  • Why PRWeb
  • How It Works
  • Who Uses It
  • Pricing

Accounts

  • Create a Free Account
  • Log in
  • Contact Us

Do not sell or share my personal information:

  • Submit via [email protected] 
  • Call Privacy toll-free: 877-297-8921

Contact Cision

Products

About

My Services
  • All News Releases
  • Online Member Center
  • ProfNet
Cision Distribution Helpline
888-776-0942
  • Legal
  • Site Map
  • RSS
  • Cookie Settings
Copyright © 2025 Cision US Inc.